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Editorial
‘Polar Spectrum’ of problems in polio eradication
Those who were optimistic about achieving wild-
virus polio eradication by 2004, or latest by 2005,
including myself, are struck by certain signals of
potential problems in a few foci of persisting virus
transmission. Such foci, although very limited in
number, have exhibited the tenacious persistence of
transmission of wild poliovirus type 1, in spite of
intensive and continuous efforts to dislodge it. To most
experts this problem might appear to be one of sub-
optimal immunization with oral polio vaccine (OPV),
both regular and supplementary, but to others it
presents an unexpected challenge of poliovirus
persistence that might demand careful assessment
and additional (better) tactics than applied earlier.
Obviously there is a geographic spectrum of ease
and difficulty in interrupting poliovirus transmission in
different countries. The purpose of this editorial is to
highlight the existence of an extremely difficult problem
in a limited number of spots in the world.  The intention
here is to define the problem so that solutions can be
designed to ensure  global eradication  before the end of
2005. Eradication must be achieved with zero error, and
with a built-in margin of safety that overcomes any
adverse eventuality. If the persistent foci of transmission
are tenacious, they must be identified and eliminated with
better strategies. Reduction of transmission by 99.999
per cent is not eradication; it has to be reduction by 100
per cent, no less.
There are 192 member nations of the World Health
Organization. By 1988, when World Health Assembly
passed resolution to eradicate polio, 67 countries had
already achieved the interruption of wild polioviruses
in their territories. In many countries the regular
childhood immunization using either injectable polio
vaccine (IPV) or OPV alone was sufficient to
interrupt transmission and to prevent local spread of
any imported virus. The very first country to achieve
this success was Finland; in 1961, when 51 per cent
of the population had received 3 doses of the Salk
vaccine, wild virus transmission ceased. The US
achieved it in 1972 by the sequential use of IPV in
children followed by OPV in mass campaigns in
children and adults followed by the exclusive use (3
doses) of OPV in the regular programme of childhood
immunization. Japan needed only two doses of OPV
per infant to eliminate wild virus transmission. Cuba
used a novel tactic of annual two-dose campaigns
and interrupted wild virus transmission. These
countries represent one end of the polar spectrum,
the easier means of interruption of wild virus
transmission.
But the eco-epidemiology of polioviruses and the
efficacy of the vaccines are not uniform throughout
the world and hence we need to have different
approaches. Interruption was less easy in some
European countries like France and Germany that
eventually succeeded by persistent and sustained
immunization pressure against the wild viruses. Yet,
they managed it by regular immunization alone, using
the standard number of doses, without supplementary
activities so vital in many developing countries.
Interruption was somewhat more difficult in other
countries, such as Taiwan and Oman, where a five-
dose OPV regimen succeeded in interruption of wild
virus transmission, as the three-dose regimen was
found  grossly insufficient.
In a number of nations in Latin America, Africa
and Asia, large-scale supplementary immunization
over many years was found necessary for interrupting
wild virus transmission. They included large nations
like Brazil and China, smaller nations like Indonesia
and Bangladesh, and island nations like Philippines
and Sri Lanka.
The difficult end of the spectrum consists of the
six countries that have failed to achieve interruption
by 2003 and have continued infection even into 2004.
They are India, Pakistan, Afghanistan, Egypt, Nigeria
and Niger.  The problem in Nigeria was the interruption
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of immunization for ‘local religious politics’ and its
resumption could interrupt the  wild virus spread.
When Nigeria succeeds Niger is likely to become
polio-free. When the western region of Pakistan
succeeds Afghanistan will (most probably) have no
further infection. Perhaps three foci may present a
formidable barrier to interrupt transmission in 2004
or even by 2005. This is not prediction, but anxiety
based on past and current performance and
epidemiology.  They are a few districts (especially
Badaun and Moradabad) in western Uttar Pradesh
(UP) in India, the Sind Province in Pakistan and the
Nile valley in Egypt.
These foci have remained infected without a break
in spite of good quality regular and supplementary
immunization (Egypt), or excellent supplementary
immunization even if the regular immunization is poor
(western UP and Sind). In these foci, types 2 and 3
viruses have been eliminated, attesting to the success
of the tactics applied in the past. Yet, in Egypt, type 1
virus has persisted in small numbers until now.
Western UP continues to export virus to many
previously uninfected districts and states, in spite of
the fact that the median number of OPV doses in
under-five children is six, mostly through
supplementary immunization. Over 95 per cent under-
five children have received more than four doses of
OPV. Thus, these foci represent the worst end of the
spectrum of our difficulty to eliminate wild virus
transmission.
If recent experience is any indication, it is unlikely
that virus transmission will simply cease in these foci
between now and the end of 2005 if we continue the
same interventions as had been applied in the past,
including in 2004. What might be the factors
determining the tenacious persistence of virus
transmission? That the three foci are in the ancient
civilizations along major rivers, Ganges in India, Indus
in Pakistan and Nile in Egypt and the fact that
predominantly Muslim communities are involved,
suggest some common factors. They may include high
density of population, relatively high birth rates and
consequent high density of infants and toddlers – the
most efficient amplifiers and transmitters of wild
poliovirus. Low income levels of families, low literacy,
low living standards with poor sanitation and hygiene
and sub-optimal health system serving the poor could
be others. In short, the ‘force of transmission’ of wild
virus may be extremely high in these foci and
interventions that worked in other poor communities
may not overcome such exceedingly high force of
transmission.
The OPV has geographic variations in efficacy -
high in Japan and other rich nations, low in Taiwan
and Oman, lower still in many developing countries.
In the foci of persistent transmission, the efficacy
may be the lowest. In UP there have been several
children with polio in spite of consuming many doses,
even 8 or more. Low vaccine efficacy spells low
effectiveness and low herd effect – factors that make
the vaccine a poor match to the task of interrupting
the transmission of the most transmissible among wild
virus types, namely type 1. In summary, the worst
end of the spectrum may be characterized by
extremely high force of wild virus transmission and
very low efficacy of OPV.
Admittedly, interventions need to be tailored
appropriately. Very high proportions of infants of 4 to
8-9 months of age need to be made completely immune
to polio by vaccination to overcome the very high force
of transmission of type 1 wild virus. Below 4 months
infants have maternal antibody. What is the best way
to immunize infants of this age? The Expanded
Programme on Immunisation (EPI) in India still
maintains the old 3-dose regimen, at 6, 10 and 14 wk.
A dose at birth is allowed but called ‘zero dose’ and
not counted for immunization coverage evaluation.
Therefore zero importance is given to ‘zero dose’.
What we need is 7-10 doses in these young infants.
Therefore, a birth dose, three more doses by 14 wk
and a fifth dose along with measles vaccine at 9
months should be the minimum in the regular age-
based immunization. We still need three more doses
by campaign every six months in order to catch all
birth cohorts for covering with 8 doses by 8-9 months
of age. Without such high speed and efficacy of
immunization, it is unlikely that we will succeed in
the three foci. The same or even higher number of
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doses at later ages, such as twenty doses by age 5 yr
may not  achieve very high immunity prevalence
among very young infants.
Where this approach is not feasible, yet another
intervention might be to add two doses of IPV at 10
and 14 wk, or better with a third dose also at nine
months.  If this is not feasible, at least one dose any
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time between 4 and 9 months may be possible.  Even
a single dose of IPV has been shown to markedly
improve immunity in Cote d’Ivoire and in Oman. Polio
experts need to grasp the worst-case scenario at the
extreme right end of the spectrum of our difficulty in
eliminating virus circulation and help these countries
to redesign our tactics for the elimination of the
scourge.
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